Co-founder and CEO wants to replace himself
![Foto: Colourbox](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article5489559.ece/ALTERNATES/schema-16_9/COLOURBOX3976368.jpg)
In the spring of 2014, Danish medtech company, Acarix, will launch a long-awaited product that has come to be known as the “blood clot alarm”. The initial plan is to market the product and generate solid sales in 3-4 European markets. A possible exit will not be on the cards until that has been achieved, explains Peter Samuelsen, co-founder and CEO in Acarix, in an interview with Medwatch.
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Medtech company secures millions from investors
For abonnenter